Assertio Holdings, Inc.
ASRT evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $151.9M
- Lead Asset:
- poziotinib (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ASRT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASRT
Assertio Holdings, Inc. is a specialty pharmaceutical company focused on the commercial launch of ROLVEDON (eflapegrastim-xnst), a long-acting G-CSF, following the sale of its legacy product portfolio in April 2026.
Key risk: Single-product dependency
BioSniper Score
Based on 5 of 6 signals
Market Cap
$151.9M
Cash Runway
—
Lead Asset
poziotinib (Phase 2)Next Catalyst
Patent_Expiry · Feb 24, 2029Financial data as of Mar 31, 2026.
Tracking 2 pipeline candidates · 1 catalyst for Assertio Holdings, Inc..
Assertio Holdings, Inc. is a specialty pharmaceutical company focused on the commercial launch of ROLVEDON (eflapegrastim-xnst), a long-acting G-CSF, following the sale of its legacy product portfolio in April 2026.
- Cash & equivalents of $33.7M as of 2026-03-31 [sec].
- Total revenue of $9.9M and net loss of -$18.9M for the period ending 2026-03-31 [sec].
- Shareholders' equity of $75.6M as of 2026-03-31 [sec].
- Completed sale of non-ROLVEDON assets (INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP) to Cosette Pharmaceuticals on April 8, 2026 for $35M upfront plus potential milestones [sec · filed 2026-04-14].
- ROLVEDON (eflapegrastim-xnst) is an FDA-approved long-acting G-CSF for febrile neutropenia in nonmyeloid malignancies, partnered with Hanmi Pharmaceutical [pipeline].
What works
- ROLVEDON is an FDA-approved product with a novel long-acting G-CSF mechanism, providing a differentiated option in the neutropenia market [pipeline].
- The $35M upfront from the asset sale provides immediate cash to fund ROLVEDON's commercial launch and operations [sec · filed 2026-04-14].
- The company has a license agreement with Hanmi Pharmaceutical for ROLVEDON, securing API supply and fixed pricing for the remaining term [pipeline].
What to weigh
- The company reported a net loss of -$18.9M for the period ending 2026-03-31, indicating ongoing operating losses [sec].
- Assertio faces significant net operating loss carryforwards that may be unusable even if profitability returns, potentially limiting future cash flows [sec_mda · as of 2026-03-16].
- The company's future depends heavily on ROLVEDON's commercial success, which is subject to payor coverage, biosimilar competition, and market acceptance [sec_mda · as of 2026-05-08].
- The company has no other marketed products after the asset sale, concentrating all commercial risk on ROLVEDON [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Asset sale of non-ROLVEDON products to Cosette for $35M upfront
“the Company also completed the sale (the " Asset Sale ") of its right, title and interest in and to the INDOCIN®, SPRIX®, SYMPAZAN®, CAMBIA®, ZIPSOR® and the recently decommercialized OTREXUP® franchises of products (collectively, the " Products ") to Cosette pursuant to the Asset Purchase Agreement, for an aggregate purchase price of $35,000,000 in cash”
SEC filings · April 14, 2026
ROLVEDON is an approved long-acting G-CSF
“ROLVEDON Generic Name: eflapegrastim-xnst Indication: Decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs Phase: Approved”
Net operating loss carryforwards may be unusable
“even if we regain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect future cash flows”
SEC MD&A · March 16, 2026
Catalyst timeline
- 2029-02-24 · Patent_Expiry · DICLOFENAC POTASSIUM — Patent expiry for NDA022202; may open the door for generic competition to a product formerly in Assertio's portfolio.
Risks & what to watch (4)›
Key risks
- Single-product dependency — After the asset sale, Assertio's entire commercial future rests on ROLVEDON, with no other marketed products to diversify risk [sec_mda · as of 2026-05-08].
- Biosimilar and generic competition
- Unusable NOL carryforwards
- Ongoing litigation and exit costs
What to watch
- ROLVEDON sales growth and market acceptance, including payor coverage and pharmacy benefit manager decisions [sec_mda · as of 2026-05-08].
- Ability to manage supply costs and enhance long-term prospects of ROLVEDON [sec_mda · as of 2026-05-08].
- Potential milestone payments from the Cosette asset sale, up to $32M for SYMPAZAN, INDOCIN, and OTREXUP [sec · filed 2026-04-14].
- Patent expiry of DICLOFENAC POTASSIUM on 2029-02-24, which may affect competitive landscape [catalyst].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Assertio Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Assertio Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.79 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~863d
No insider transactions in the last 180 days
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
65
Total value held
$47.0M
| Holder | Shares | Value |
|---|---|---|
| nantahala capital management, llc | 692,335 | $13.2M |
| vanguard capital management llc | 268,952 | $5.1M |
| opaleye management inc. | 265,707 | $5.1M |
| renaissance technologies llc | 228,599 | $4.4M |
| edgewood management llc | 107,517 | $2.0M |
| blackrock, inc. | 90,035 | $1.7M |
| jane street group, llc | 79,436 | $1.5M |
| geode capital management, llc | 76,314 | $1.5M |
| walleye capital llc | 65,926 | $1.3M |
| sei investments co | 54,940 | $1.0M |
Showing top 10 of 65 institutional holders of Assertio Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.6%
- Days to cover
- 1.1
- Shares short
- 289,282
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASRT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Assertio Holdings, Inc.?
Assertio Holdings, Inc. is a specialty pharmaceutical company focused on the commercial launch of ROLVEDON (eflapegrastim-xnst), a long-acting G-CSF, following the sale of its legacy product portfolio in April 2026.
What is Assertio Holdings, Inc.'s lead drug candidate?
Assertio Holdings, Inc.'s most advanced tracked candidate is poziotinib (Phase 2) for Under investigation for non-small cell lung cancer tumors with various mutations..
What is Assertio Holdings, Inc.'s next catalyst?
Assertio Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA022202" — expected February 24, 2029.
Who is the CEO of Assertio Holdings, Inc.?
Mr. Mark L. Reisenauer is the chief executive officer of Assertio Holdings, Inc. (ASRT).
Where is Assertio Holdings, Inc. headquartered?
Assertio Holdings, Inc. (ASRT) is headquartered in Lake Forest, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.